Pharmaceutical Contract Development and Manufacturing Market

Thermo Fisher Scientific (US) and Catalent (US) are Leading Players in the Pharmaceutical Contract Development and Manufacturing Market

The global pharmaceutical contract development and manufacturing market is projected to reach USD 126.6 billion by 2024 from USD 90.0 billion in 2019, at a CAGR of 7.1%. The rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs are the primary growth factors for this market. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are expected to offer significant growth opportunities for players in this market. However, the introduction of serialization and changing trade policies between countries are some of the major market challenges.

Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie Inc. (US), Aenova Group (Germany), Consort Medical plc (UK), Almac Group (UK), Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), and Evonik Industries AG (Germany) are some key players in this market. These companies are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies such as product launches, acquisitions, and expansions.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific (US) is one of the prominent players operating in the pharmaceutical contract development and manufacturing market. The company has a strong geographic footprint and serves over 400,000 customers in pharmaceutical and biotech companies. It also has an extensive distribution channel across the globe. Thermo Fisher Scientific offers CDMO services through Pantheon. The company focuses on expanding its manufacturing capabilities for delivering the highest-quality medicines. In line with this, the company and invested USD 150 million in its pharma services business segment for the expansion of its manufacturing capacity for sterile liquids and lyophilized product development & commercial manufacturing. The company’s extensive R&D activities enable it to increase its capabilities in technologies, software, and services.

Catalent (US) is one of the leading providers of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. It mainly focuses on service launches, expansions, acquisitions, partnerships, and collaborations for growth. For instance, in May 2019, the company launched its new OneBio SuiteSM for the integrated development, manufacturing, and the clinical supply of biologic drugs at the BIO International Convention in Philadelphia, US. Catalent also focuses on investing in its facilities and technologies for the further expansion of its manufacturing capabilities—for example, the company invested USD 27 million for the commercialization of its oral disintegrating tablet technology, Zydis Ultra. Through such innovative investments, the company further focuses on diversifying its offerings and services. Catalent has also worked toward strengthening its geographical footprint in the pharmaceutical contract development and manufacturing market.

Related Reports:

Pharmaceutical Contract Development and Manufacturing Market by Service (Pharmaceutical, Biologics, Active Pharma Ingredients, Tablet, Capsule, Parenteral, Oral Liquid), End User (Big Pharma, Small Pharma, Generic Pharma, CRO) - Global Forecast to 2024

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Report Code
PH 7263
RI Published ON
7/29/2019
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Pharmaceutical Contract Development and Manufacturing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved